Observed Signal · Nov 3, 2026 · corporate_event · Source: SEC API · Impact: 3.2/5
8-K Financial Filing Analysis for CGI (2026-11-03)
On November 3, 2026, Corcept Therapeutics Incorporated furnished a Form 8-K under Items 2.02 and 7.01 announcing the release of its financial results for the third quarter ended September 30, 2026, along with a corporate update. The detailed financial statements and operational metrics were provided via an accompanying press release attached as Exhibit 99.1. The filing fulfills regulatory disclosure requirements under Regulation FD without formal incorporation into Securities Act registration statements.
Furnishes quarterly financial results and operational updates for Q3 2026, serving as the procedural vehicle for Corcept's earnings release.
Track CGI Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Corcept Therapeutics furnished its Q3 2026 financial results for the period ended September 30, 2026, via an 8-K press release notice on November 3, 2026.
- The disclosure was furnished pursuant to Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure), with Exhibit 99.1 containing the full press release.
- The filing was formally signed and authorized by Chief Financial Officer Atabak Mokari on November 3, 2026.
Connected Companies & Entities
1 Entity mappedRelated Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
8-K Financial Filing Analysis for Corning (2026-10-27)
On October 27, 2026, Corning Incorporated filed a Form 8-K under Item 2.02 (Results of Operations and Financial Condition) announcing the release of its financial results for the third quarter ended September 30, 2026. The financial results were furnished via an accompanying press release issued as Exhibit 99. As a standard Item 2.02 furnishing, the release communicates quarterly operational performance and condition to shareholders and the market without being formally deemed 'filed' under Section 18 of the Exchange Act.
10-Q Financial Filing Analysis for CGI (2026-07-29)
Corcept Therapeutics reported strong financial results for the second quarter ended June 30, 2026, generating net product revenue of $256.1 million, a 31.7% increase year-over-year. Growth was accelerated by the commercial launch of Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer, which contributed $47.6 million in debut quarterly sales alongside core hypercortisolism therapies. On the regulatory and legal front, Corcept resubmitted its relacorilant NDA for endogenous Cushing's syndrome with a PDUFA date set for December 17, 2026, while the Court of Appeals affirmed a non-infringement ruling in the Teva patent litigation and denied a rehearing en banc in July 2026.
8-K Financial Filing Analysis for Cognizant (2026-10-29)
On October 29, 2026, Cognizant Technology Solutions Corporation filed a Form 8-K under Items 2.02 and 7.01 furnishing its financial results for the third quarter ended September 30, 2026. The disclosure announces the release of the company's Q3 2026 earnings press release (Exhibit 99.1), investor infographic (Exhibit 99.2), and investor presentation (Exhibit 99.3). In accordance with standard regulatory procedure for earnings announcements, the detailed financial materials are furnished rather than formally filed under Section 18 of the Securities Exchange Act of 1934.
Receive all future signals for CGI & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.